LCR1与LCR2:两种多分析物血液检测评估无肝硬化或肝硬化患者肝癌风险
该研究基于前瞻性收集样本的回顾性分析,构建并内部验证两种序贯血液检测(LCR1和LCR2)用于肝癌早期预测。共纳入9892例患者(85.9%无肝硬化),随访5.9年。LCR1高危后LCR2高危的2027例中检出167例肝癌,需筛查12例发现1例肝癌;阴性预测值99.5%,高于标准监测的98.0%。
要点
- LCR1联合LCR2可在无肝硬化患者中识别肝癌高危人群。
- 高危组需筛查12例发现1例肝癌,标准监测需筛查7例发现1例。
- LCR1/LCR2阴性预测值99.5%,高于标准监测的98.0%。
核心结论
- 在慢性肝病患者中,LCR1和LCR2检测可识别肝癌高风险者,包括无肝硬化患者。
研究设计与样本
- 回顾性分析前瞻性收集的 ongoing 队列标本,共9892例患者,85.9%无肝硬化,随访5.9年(IQR 4.3-9.4)。
主要发现
- LCR1和LCR2的时间依赖AUROC在构建集与验证集随机子集中无差异。
- LCR1高危后LCR2高危的2027例中检出167例肝癌(113例肝硬化,54例无肝硬化),需筛查12例发现1例肝癌。
- 2026例未筛查者中阴性预测值99.5%(95%CI 99.0-99.7),含11例无肝硬化肝癌。
- 标准监测在755例筛查者中检出113例肝癌,需筛查7例发现1例,但3298例未筛查者中阴性预测值98.0%(95%CI 97.5-98.5;Z=4.3;P<0.001),含42例无肝硬化肝癌。
关键数值与推荐
- LCR1组合(Cox模型):载脂蛋白A1、结合珠蛋白、性别、年龄、γ-谷氨酰转肽酶、α2-巨球蛋白。
- LCR2在LCR1基础上加入甲胎蛋白以提高特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No blood test has been shown to be effective in the prediction of primary liver cancer in patients without cirrhosis. AIM: To construct and internally validate two sequential tests for early prediction of liver cancer. These tests enable an algorithm which could improve the performance of the standard surveillance protocol recommended (imaging with or without AFP), limited to patients with cirrhosis. METHODS: We performed a retrospective analysis in prospectively collected specimens from an ongoing cohort. We designed an early sensitive high-risk test (LCR1) that combined (using Cox model) hepatoprotective proteins (apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker of fibrosis (alpha2-macroglobulin). To increase the specificity, we then combined (LCR2) these components with alpha-fetoprotein. RESULTS: A total of 9892 patients, 85.9% without cirrhosis, were followed up for 5.9 years [IQR: 4.3-9.4]. LCR1 and LCR2 time-dependent AUROCs were not different in construction and validation randomised subsets. Among 2027 patients with high-LCR1 then high-LCR2, 167 cancers (113 with cirrhosis, 54 without cirrhosis) were detected, that is 12 patients needed to screen one cancer. The negative predictive value was 99.5% (95% CI 99.0-99.7) in the 2026 not screened patients (11 cancers without cirrhosis) higher than the standard surveillance, which detected 113 cancers in 755 patients screened, that is seven patients needed to screen one cancer, but with a lower negative predictive value 98.0% (97.5-98.5; Z = 4.3; P < 0.001) in 3298 not screened patients (42 cancers without cirrhosis). CONCLUSIONS: In patients with chronic liver disease the LCR1 and LCR2 tests identify those with a high risk of liver cancer, including in those without cirrhosis. NCT01927133.
引用
- Poynard T, Peta V, Deckmyn O, et al. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther. 2018. PMID: 30569507. doi:10.1111/apt.15082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。